# The association between major depressive disorder and cannabis use disorder: A meta-analysis and meta-regression analysis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/major-depressive-disorder-cannabis-use/ > **Published:** 2026-04-27T07:02:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:02:40-04:00 > **Clinical Summary:** Explore the major depressive disorder cannabis use link through a meta-analysis revealing prevalence and clinical insights on MDD and cannabis use disorder. --- CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Journal Journal of psychiatric research Study Type Meta-Analysis Population Human participants Why This Matters This item covers developments relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and clinical practice. Clinicians monitoring evidence in this area should review the source material. Clinical Summary Major Depressive Disorder (MDD) and [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) (CUD) frequently co-occur, yet prevalence estimates vary widely across settings. This meta-analysis updates the evidence on the bidirectional association between MDD and CUD, emphasizing current-diagnosis subgroups, which are the most clinically relevant. Following PRISMA and MOOSE guidelines, we systematically searched PubMed, Google Scholar, and SciELO. Random-effects models estimated current-diagnosis prevalence of MDD among individuals with CUD and of CUD among individuals with MDD. Subgroup analyses differentiated psychiatric and community samples. Sensitivity analyses (leave-one-out) and Egger’s tests assessed robustness and publication bias. Meta-regressions evaluated demographic, methodological, and geographic moderators. In total, 55 studies comprising 3,279,774 individuals were included (454,547 and 112,328 living with CUD and MDD, respectively). Current MDD prevalence among individuals with CUD was elevated in both ps Dr. Caplan’s Take “This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.” Clinical Perspective 🧠 Clinicians should review this item in the context of their current practice and patient population. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20association%20between%20major%20depressive%20disorder%20and%20cannabis%20use%20disorder%3A%20A%20meta-analysis%20and%20met...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fthe-association-between-major-depressive-disorder-and-cannabis-use-disorder%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fthe-association-between-major-depressive-disorder-and-cannabis-use-disorder%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20association%20between%20major%20depressive%20disorder%20and%20cannabis%20use%20disorder%3A%20A%20meta-analysis%20and%20met...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fthe-association-between-major-depressive-disorder-and-cannabis-use-disorder%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41793962/](https://pubmed.ncbi.nlm.nih.gov/41793962/) Table of Contents - [FAQ](#FAQ)[How many studies and people were included in this meta-analysis?](#How_many_studies_and_people_were_included_in_this_meta-analysis) - [Why does the meta-analysis focus on current diagnoses?](#Why_does_the_meta-analysis_focus_on_current_diagnoses) - [How did the researchers search for and combine the studies?](#How_did_the_researchers_search_for_and_combine_the_studies) - [Related](#Related) ## FAQ ### How many studies and people were included in this meta-analysis? The meta-analysis included 55 studies covering 3,279,774 individuals. Of these, 454,547 were living with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and 112,328 were living with major depressive disorder. These two groups formed the basis for estimating how common each condition is among people with the other. ### Why does the meta-analysis focus on current diagnoses? The authors emphasize current-diagnosis subgroups because they are the most clinically relevant. The analysis looks at the association in both directions: how common current major depressive disorder is among people with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder, and how common current cannabis use disorder is among people with depression. It updates earlier evidence on this bidirectional link. ### How did the researchers search for and combine the studies? Following PRISMA and MOOSE guidelines, the researchers systematically searched PubMed, Google Scholar and SciELO. They used random-effects models to estimate current-diagnosis prevalence, and subgroup analyses separated psychiatric samples from community samples. Meta-regressions also evaluated whether demographic, methodological or geographic factors acted as moderators. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Medical Cannabis Significantly Reduced Use of Opioids and Other Rx Drugs](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) Explore how [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) impacts opioid and prescription drug use, providing insights relevant to [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. [Read More](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) [Most-prescribed medicinal cannabis type 'not supported by evidence' | AusDoc](https://cedclinic.com/most-prescribed-medicinal-cannabis-type-evidence-review/) Review evidence challenges surrounding commonly prescribed medicinal cannabis types and implications for clinical practice. [Learn More](https://cedclinic.com/most-prescribed-medicinal-cannabis-type-evidence-review/) [New research suggests cannabinoids like CBD and CBG may help improve fatty liver disease.](https://cedclinic.com/cannabinoids-fatty-liver-clinical-relevance/) Discover emerging research on cannabinoids’ therapeutic potential beyond mental health, including [liver disease](https://cedclinic.com/cannabis-compounds-may-reverse-fatty-liver-disease/) improvements. [Explore Research](https://cedclinic.com/cannabinoids-fatty-liver-clinical-relevance/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).